Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
Albert Font, Begoña Mellado, Miguel Ángel Climent, Juan Antonio Virizuela, Stéphane Oudard, Javier Puente, Daniel Castellano, Aranzazu González del Alba, Álvaro Pinto, Rafael Morales‐Barrera, Alejo Rodríguez‐Vida, Pedro L. Fernández, Cristina Teixidó, Pedro Jares, Ibán Aldecoa, Neil Gibson, Flavio Solca, Shoubhik Mondal, Robert M. Lorence, Josep Serra, Francisco X. Real
Topics & Concepts
CohortMedicineAfatinibInternal medicineOncologyMetastatic Urothelial CarcinomaClinical endpointStage (stratigraphy)UrologyBladder cancerCancerClinical trialUrothelial carcinomaEpidermal growth factor receptorBiologyErlotinibPaleontologyBladder and Urothelial Cancer TreatmentsFibroblast Growth Factor ResearchLung Cancer Treatments and Mutations